Cell Source, Inc. Uncategorized Contracts & Agreements
14 Contracts & Agreements
- Amendment No. 2 to Veto Cell Production and Clinical Trial Program Agreement, dated as of August 7, 2019, between Cell Source Limited and the University of Texas M.D. Cancer Center (Filed With SEC on August 19, 2024)
- Amendment No. 3 to Veto Cell Production and Clinical Trial Program Agreement, dated as of May 1, 2023, between Cell Source Limited and the University of Texas M.D. Cancer Center (Filed With SEC on August 19, 2024)
- Amendment No. 4 to Sponsored Research Agreement dated November 6, 2023 between the University of Texas MD Anderson Cancer Center and Cell Source Ltd (Filed With SEC on November 9, 2023)
- Amendment No. 3 to Sponsored Research Agreement dated November 15, 2022 between the University of Texas MD Anderson Cancer Center and Cell Source Ltd (Filed With SEC on November 9, 2023)
- Amendment No. 2 to Sponsored Research Agreement dated October 18, 2021 between the University of Texas MD Anderson Cancer Center and Cell Source Ltd (Filed With SEC on April 15, 2022)
- Amendment No. 2 to Sponsored Research Agreement dated October 18, 2021 between The University of Texas M.D. Anderson Cancer Center and Cell Source Limited (Filed With SEC on November 15, 2021)
- AMENDMENT NO. 1 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT (Filed With SEC on May 20, 2019)
- SPONSORED RESEARCH AGREEMENT (Filed With SEC on April 1, 2019)
- ยง 1 Subject matter (Filed With SEC on April 1, 2019)
- By:Name:Title:Cell Source, Inc. (Filed With SEC on November 16, 2015)
- CONSULTING/ADVISORY AGREEMENT (Filed With SEC on June 10, 2015)
- CELL SOURCE, INC. 65 Yigal Alon Street Tel Aviv, Israel 67433 (Filed With SEC on June 3, 2015)
- BRIDGEFUNDING AGREEMENT Made and signed as of the 23rd day of October,2013 (Filed With SEC on September 23, 2014)
- AMENDMENT NO.1 TO REGISTRATION RIGHTSAGREEMENT (Filed With SEC on August 8, 2014)
